A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
复制标题
DOI：
10.1016/j.breast.2014.06.017
复制
发表时间：
2014-10-01
期刊：
影响因子：
3.9
通讯作者：
Cortes, Javier
中科院分区：
文献类型：
--
作者：
Llombart-Cussac, Antonio;Pivot, Xavier;Cortes, Javier
背景：缺乏“预后不良”或“侵袭性”晚期乳腺癌的循证定义。患者和方法：我们利用2203例接受一线化疗加贝伐单抗治疗her2阴性晚期乳腺癌的患者的数据制定了预后因素指数。结果：与OS恶化最密切相关的危险因素为：无病间期= 3个受累器官部位；既往蒽环类药物和/或紫杉烷治疗；三阴性乳腺癌（TNBC）；表现状态2或既往的镇痛/皮质类固醇治疗。相比之下，>= 3的患者死亡风险增加了3倍
Background: Evidence-based definitions of 'poor-prognosis' or 'aggressive' advanced breast cancer are lacking.Patients and methods: We developed a prognostic factor index using data from 2203 patients treated with first-line chemotherapy plus bevacizumab for HER2-negative advanced breast cancer.Results: The risk factors most closely associated with worse OS were: disease-free interval = 3 involved organ sites; prior anthracycline and/or taxane therapy; triple-negative breast cancer (TNBC); and performance status 2 or prior analgesic/corticosteroid treatment. Risk of death was increased threefold in patients with >= 3 versus